Laurion Capital Management LP, along with co-managing members Benjamin Alexander Smith and Janaka Sheehan Maduraperuma, filed Amendment No. 3 to a beneficial ownership statement with the SEC on November 3, 2026, disclosing a combined holding of 4,300,888 shares of Pyxis Oncology, Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Laurion Capital Management LP and its two co-managing members each report beneficial ownership of 4,300,888 shares of Pyxis Oncology common stock.
  • Percent of class: The reported position represents 5.16% of Pyxis Oncology's outstanding common stock.
  • Shared voting and dispositive power only: Each reporting person holds 0 shares with sole voting or sole dispositive power; all 4,300,888 shares are held with shared voting and shared dispositive power.
  • Triggering event date: The event requiring this filing occurred on September 30, 2026, according to the statement.
  • Underlying fund: The filing identifies Laurion Capital Master Fund Ltd. as having the right to receive dividends or sale proceeds from more than 5% of the reported shares.
  • Amendment number: This is the third amendment (Amendment No. 3) to the original filing, signed by General Counsel and CCO Jason Riesel on behalf of Laurion Capital Management LP.

Laurion Capital's Position in Pyxis Oncology as of September 30, 2026

According to the filing, Laurion Capital Management LP is a Delaware limited partnership that serves as investment adviser to certain funds and accounts collectively referred to as the "Laurion Funds." The shares of common stock reported in this statement are directly held by those funds. Pyxis Oncology, Inc., the issuer, is a clinical-stage oncology company headquartered at 321 Harrison Avenue, Boston, MA 02118, with common stock carrying a par value of $0.001 per share and CUSIP number 747324101. The filing does not describe the specific clinical programs or pipeline assets of the issuer.

The two individual reporting persons, Mr. Benjamin Alexander Smith, a citizen of the United States, and Mr. Janaka Sheehan Maduraperuma, a citizen of the United Kingdom, are each identified as co-managing members of Laurion Capital GP LLC, the general partner of Laurion Capital Management LP. Both individuals are classified as type "HC, IN" (holding company and individual) in the filing, while Laurion Capital Management LP is classified as type "IA, PN" (investment adviser and partnership). All three reporting persons share identical beneficial ownership figures of 4,300,888 shares, representing 5.16% of the class, with no sole voting or dispositive power reported for any party.

The filing states that the shares "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The business address for all reporting persons is listed as 360 Madison Avenue, Suite 1900, New York, NY 10017. The statement also notes that the filing "should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein."

What Was Disclosed

Laurion Capital Management LP, Benjamin Alexander Smith, and Janaka Sheehan Maduraperuma jointly disclosed beneficial ownership of 4,300,888 shares, equal to 5.16%, of Pyxis Oncology, Inc. (NASDAQ:PYXS) common stock, in Amendment No. 3 filed November 3, 2026, with a triggering event date of September 30, 2026.